Skip to search formSkip to main contentSkip to account menu

telaprevir

Known as: (1S,3AR,6as)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide 
An orally available peptidomimetic small molecule with activity against hepatitis C virus (HCV). Telaprivir is a selective protease inhibitor that… 
National Institutes of Health

Related topics

Related topics

7 relations
HCV NS3/4A Protease Inhibitors [MoA]Hepatitis C

Narrower (4)

IncivekLY-570310MP-424VX 950

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Direct‐Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost‐Saving
Highly Cited
2014
Highly Cited
2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Highly Cited
2014
Highly Cited
2014
Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C… 
Highly Cited
2014
Highly Cited
2014
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse event. The… 
Highly Cited
2013
Highly Cited
2013
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Review
2012
Review
2012
New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
Introduction:  Hepatitis C virus (HCV) affects approximately 3% of the world population. The current standard of care for… 
Highly Cited
2012
Highly Cited
2012
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
Highly Cited
2012
Highly Cited
2012
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
Summary.  The aims of this phase III study were to assess the efficacy and safety of telaprevir in combination with peginterferon… 
Review
2012
Review
2012
HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.
Hepatitis C virus (HCV) is the cause of more than three-quarters of liver-related deaths in HIV-seropositive individuals and it… 
Review
2012
Review
2012
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
Summary.  The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)